How Generic Pharma Manufacturers Can Rebuild Margins Inside The Four Walls

By Nero Haralalka, director – U.S. Consulting, TBM Consulting Group

Generic drug manufacturers face relentless pressure from price erosion, customer concentration, and supply instability. In that environment, the most reliable path to margin improvement is no longer pricing power — it is operational performance inside the four walls.

As products mature and competition intensifies, prices fall while expectations for quality, reliability, and service continue to rise. The pricing dynamic is well established: once multiple competitors enter, prices on many molecules fall 70 percent–80 percent from pre‑generic levels and can ultimately drop more than 90 percent, turning formerly attractive products into high‑volume, low‑margin commodities. At the same time, a shrinking number of powerful purchasing consortia controls most generic volume, further compressing margins. Thin margins, growing portfolio complexity, and limited tolerance for failure create an unforgiving equation.

Operational execution becomes one of the few levers manufacturers can still control. Lean and Six Sigma have proved effective in this context. By systematically reducing waste, stabilizing processes, and unlocking capacity from existing assets, they enable lower true operating cost while improving quality and service. The manufacturers that endure are not simply the lowest‑price suppliers but those that deliver predictable output, consistent quality, and reliable supply at the lowest sustainable cost.

The Public Health Stakes Of Plant-Level Reliability

Drug shortages are often framed as a policy or purchasing problem, but many root causes start inside individual plants — quality breakdowns, maintenance backlogs, slow deviation resolution, and underinvestment in equipment and people. When sites run near full capacity with little redundancy, even a short shutdown for remediation can trigger months‑long supply disruptions. From a Lean perspective, this is a system operating with excessive variation and no capacity protection.

Plant reliability is now directly tied to patient access: in concentrated markets, the failure of a single high‑volume line can force hospitals and payers into emergency sourcing, substitutions, or rationing, especially for injectables and oncology products. Regulators and purchasers are increasingly exploring ways to recognize and reward manufacturers that deliver reliable supply and mature quality systems. For generic manufacturers, that shift turns operational reliability and resilience into a differentiating capability with real economic value in markets where price is largely fixed.

Operations As The Remaining Profit Lever

Once a molecule is fully generic, manufacturers have little influence over price, especially when selling to consolidated buying groups. Raising prices rarely restores margin for long; competitors follow and buyers shift volume to the lowest bid. What remains under your control is the cost, reliability, flexibility, and responsiveness of your own operations.

Lean, Six Sigma, and operational excellence have repeatedly shown they can cut unit cost while improving quality and service by reducing downtime, shortening cycle times, improving yields, and eliminating non‑value‑added work without sacrificing compliance. Applied to high‑volume, mature generics, the same toolkit can rebuild sustainable margins even after price erosion has run its course.

Four operational levers tend to drive the majority of “inside the four walls” margin recovery in generic plants:

• Uptime and asset utilization
• Changeover and campaign efficiency
• Yield and right‑first‑time quality
• Planning discipline and flow

Each is familiar in principle, but in a thin‑margin environment, the way they are attacked must be disciplined, focused, and grounded in an end‑to‑end view of the value stream.

Uptime: Stabilizing The Constraint

Many generic facilities run with one or two true bottleneck assets per product family — often compression, coating, filling, or packaging lines — that effectively set the plant’s capacity. Equipment reliability studies in pharma consistently show that unplanned downtime on these constraint resources drives a disproportionate share of lost volume and expediting costs. Lean teaches that performance at the constraint governs the performance of the entire system.

A Lean Six Sigma–based reliability program typically focuses on:

• Clear definition of what constitutes downtime and minor stops, with transparent loss trees and overall equipment effectiveness (OEE) tracking at the line level.
• Standardized work for cleaning, setup, and changeovers, with visual management and tiered escalation for emerging issues.
• Risk‑based preventive and predictive maintenance plans aligned to actual failure modes, not just OEM calendars.

In high‑volume generics, stabilizing the constraint increases usable capacity without capital, lowers conversion cost, and creates the margin buffer needed to address quality issues proactively rather than reactively.

Changeovers: Reducing Complexity Penalties

Generic portfolios often expand over time to accommodate strengths, pack sizes, and customer‑specific presentations. On the shop floor, that translates into complex campaign schedules with frequent changeovers, partial batches, and sequence‑dependent cleaning. Each additional changeover adds time loss, error risk, and potential yield loss at start-up.

Lean manufacturers that have tackled this effectively often start with a detailed mapping of:

• actual time by activity for representative changeovers (cleaning, line clearance, setup, QA checks)
• the “hidden factory” of micro‑stops, retries, and rework that accompany changeovers
• SKU and customer profitability, including the full burden of changeover and small‑lot penalties.

From there, they apply a mix of SMED (single‑minute exchange of die) practices, SKU and pack rationalization, and resequencing of campaigns to reduce complexity penalties. In some cases, simply grouping SKUs into rational family campaigns and eliminating the lowest‑value variants can unlock meaningful OEE gains and reduce indirect labor, documentation, and QA burden.

Yield And Right‑First‑Time Quality: Turning Scrap Into Capacity

Rising material, energy, and labor costs leave little room for yield loss or rework in generic manufacturing. At the same time, regulatory expectations increasingly emphasize data integrity, process capability, and robust deviation management.

Operational excellence programs in pharma have shown that a structured focus on right‑first‑time (RFT) performance can improve both cost and compliance. Elements often include:

• detailed Pareto analysis of deviations, batch rejections, and rework, with cross‑functional problem solving at the “gemba” for top issues
• standard work and training for critical operations, with mistake‑proofing where feasible
• feedback loops between quality, technical services, and operations to address chronic formulation, process, or equipment fit problems.

Planning And Flow: Making Capacity Real

Even with strong equipment performance, weak planning creates instability. Lean systems emphasize flow — connecting demand to constrained capacity through realistic, executable plans.

Leading manufacturers reinforce this through:

• constraint‑based production planning aligned to tender demand and API availability
• a daily tiered management system with visual controls for schedule adherence, WIP, and bottleneck performance
• predefined response scenarios for demand spikes, outages, or API disruptions.

These practices help convert theoretical capacity into reliable supply performance, reducing the need for premium freight, overtime, and emergency changes to campaign plans. They also create a foundation for improving credibility with customers and regulators.

Why This Matters To Buyers And Regulators

As shortages persist, buyers and policymakers are increasingly focused not just on price but on who can reliably supply essential medicines. Manufacturers that demonstrate high OEE at constraints, disciplined changeovers, strong yields, and predictable planning are better positioned to retain volume and participate sustainably.

Lean and Six Sigma are central to building those capabilities. Attacking waste and unreliability inside the four walls is no longer optional; it is fundamental to being a preferred supplier in a system where reliability is a public health concern.

A Practical Starting Point: The Four Walls Margin Reset

The scope of “fixing operations” across a multisite network can feel overwhelming, especially for organizations already stretched thin. A more pragmatic approach is to start small and focused: select one product family, at one site, and run a targeted “four walls margin reset” centered on uptime, changeovers, yield, and planning.

A typical 12- to 18-week effort might include:

1. Define the focus area
   Choose a molecule or product family with relevance to patient care and business results — often a high‑volume, thin‑margin product that has experienced service or quality issues.
2. Build the value‑stream view
   Map the end‑to‑end flow from API receipt through packaging and release, quantifying losses from downtime, changeovers, scrap, rework, and waiting at each step.
3. Stabilize the constraint
   Establish OEE baselines for the true bottleneck asset, implement simple visual controls, and address the top drivers of unplanned downtime and speed loss with cross‑functional problem‑solving.
4. Attack changeover losses
   Analyze changeover time distribution, standardize best practices, separate internal from external tasks, and rationalize the campaign sequence and SKU mix where possible.
5. Improve yield and RFT
   Prioritize the top deviation and scrap causes, run root cause analyses at the line, and implement targeted fixes in procedures, training, or equipment settings.
6. Tighten planning and daily management
   Align production plans with realistic constraint capacity, introduce a tiered huddle structure, and monitor a small set of leading indicators for schedule adherence and flow.

By pilot’s end, the result is measurable margin improvement, better service, and a repeatable playbook that scales across the network.

From Survival To Sustainable Participation

Generic pharma economics are unlikely to reverse. Prices will remain low, and societal dependence on these products will continue to grow. In that environment, the question is not whether improvement is possible, but where to start.

Through a disciplined Lean and Six Sigma focus on reliability, changeovers, yield, and flow — beginning with one product family and one site — generic manufacturers can rebuild margins, strengthen supply reliability, and position themselves as indispensable contributors to resilient healthcare systems.

If your organization is facing price pressure, supply instability, or rising complexity, a targeted operational excellence review can identify the highest-value improvement opportunities and build a plan to capture them.

About The Author:

Nero Haralalka is director, US Consulting, at TBM Consulting Group. He is a Lean Sigma Master Black Belt with 35 years of experience in the areas of operational excellence, product development, statistical modeling (including the use of AI), and root cause problem solving. Haralalka has a master’s degree in mechanical engineering from the Illinois Institute of Technology in Chicago and a B.S. in mechanical engineering from the Birla Institute of Technology in Ranchi, India. He also has AAMI QSR Certification.